Skip to main content
. 2020 Apr 11;59(11):3303–3313. doi: 10.1093/rheumatology/keaa084

Fig. 2.

Fig. 2

ACR20, ACR50 and ACR70 responses at week 12 (NRI)

**P < 0.01, ***P < .001 vs PBO. NRI: non-responder imputation; PBO: placebo; UPA: upadacitinib.